Milestone Pharmaceuticals EPS Ratio 2011-2026 | MIST

EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.

The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares^[1]

EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.

A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.

EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.

Annual EPS Ratio Milestone Pharmaceuticals

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-1.39	-1.38	-1.02	-1.7	3.5	72.6	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
72.6	-1.7	11.8

Quarterly EPS Ratio Milestone Pharmaceuticals

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-0.12	-0.2	-0.31	-	-0.14	-0.14	-0.21	-	-0.35	-0.37	-0.35	-	-0.34	-0.39	-0.33	-	-0.34	0.02	-0.3	-	-0.4	-0.53	-0.67	-	-0.52	-1.04	-17.3	-	-20.2	-12.7	-15.6	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
0.02	-20.2	-3.03

References

Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.

EPS Ratio of other stocks in the Biotechnology industry

Issuer	EPS Ratio	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-15.4	-	2.43 %	$ 254 M	Germany
Aptorum Group Limited APM	-0.78	$ 0.82	-3.48 %	$ 4.47 M	China
Rigel Pharmaceuticals RIGL	20.4	$ 33.23	-4.03 %	$ 584 M	USA
Graybug Vision GRAY	-1.97	-	-11.23 %	$ 9.65 M	USA
I-Mab IMAB	-7.66	-	-	$ 866 M	China
Acer Therapeutics ACER	-1.66	-	2.71 %	$ 14 M	USA
Biophytis SA BPTS	-0.26	-	-13.47 %	$ 169 M	France
Ampio Pharmaceuticals AMPE	-10.7	-	-11.43 %	$ 502 K	USA
Apellis Pharmaceuticals APLS	0.18	$ 20.15	-2.68 %	$ 2.54 B	USA
AbCellera Biologics ABCL	-0.49	$ 3.72	-2.75 %	$ 1.11 B	Canada
Athersys ATHX	-0.39	-	3.77 %	$ 22.4 M	USA
Midatech Pharma plc MTP	-31	-	-18.52 %	$ 27.3 M	Britain
AVEO Pharmaceuticals AVEO	-1.63	-	-	$ 521 M	USA
Axsome Therapeutics AXSM	-3.68	$ 163.7	-1.61 %	$ 8.14 B	USA
BridgeBio Pharma BBIO	-3.78	$ 64.66	-1.37 %	$ 12.4 B	USA
Brainstorm Cell Therapeutics BCLI	-2.31	-	-2.5 %	$ 5.88 M	USA
BioDelivery Sciences International BDSI	0.85	-	-4.8 %	$ 255 M	USA
Burford Capital Limited BUR	75.3	$ 8.52	-2.46 %	$ 1.39 B	Britain
Adverum Biotechnologies ADVM	-6.62	-	-	$ 86.2 M	USA
CymaBay Therapeutics CBAY	-0.99	-	-	$ 3.45 B	USA
Avid Bioservices CDMO	-2.23	-	-	$ 789 M	USA
Certara CERT	-0.01	$ 7.16	1.49 %	$ 1.15 B	USA
ARCA biopharma ABIO	-3.87	-	1052.0 %	$ 415 M	USA
Checkpoint Therapeutics CKPT	-1.42	-	-	$ 169 M	USA
Caladrius Biosciences CLBS	-2.4	-	-16.75 %	$ 25.8 M	USA
Alpine Immune Sciences ALPN	-1.73	-	-	$ 2.17 B	USA
Clovis Oncology CLVS	-2.29	-	-7.23 %	$ 13 M	USA
Acorda Therapeutics ACOR	-204	-	-24.86 %	$ 820 K	USA
Checkmate Pharmaceuticals CMPI	-2.84	-	-	$ 231 M	USA
Capricor Therapeutics CAPR	-0.83	$ 25.91	-3.56 %	$ 694 M	USA
Catalyst Pharmaceuticals CPRX	1.75	$ 24.0	0.5 %	$ 2.93 B	USA
Acasti Pharma ACST	-0.79	-	4.01 %	$ 150 M	Canada
Codexis CDXS	-0.89	$ 0.99	-3.28 %	$ 72.7 M	USA
Corvus Pharmaceuticals CRVS	-0.56	$ 17.75	-0.79 %	$ 852 M	USA
CTI BioPharma Corp. CTIC	-0.81	-	-	$ 1.2 B	USA
CohBar CWBR	-4.2	-	-15.44 %	$ 2.2 M	USA
Cyclacel Pharmaceuticals CYCC	-504	-	-5.98 %	$ 34.1 M	USA
Cyclacel Pharmaceuticals CYCCP	-504	-	-4.36 %	$ 27 M	USA
Deciphera Pharmaceuticals DCPH	-2.29	-	-	$ 2.18 B	USA
CureVac N.V. CVAC	-2.21	-	-	$ 867 M	Germany
Aeterna Zentaris AEZS	-0.07	-	5.93 %	$ 314 M	Canada
Denali Therapeutics DNLI	-2.57	$ 20.02	-4.67 %	$ 3.29 B	USA
AgeX Therapeutics AGE	-13.7	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	-24.9	-	-	$ 1.01 B	USA
Eton Pharmaceuticals ETON	-0.04	$ 17.54	-3.36 %	$ 450 M	USA
Entasis Therapeutics Holdings ETTX	-1.09	-	-	$ 105 M	USA
Evofem Biosciences EVFM	10.4	-	7.55 %	$ 38.1 M	USA